CGRP Therapies May Reduce Migraine Days

Systematic review found high-certainty evidence for several calcitonin gene–related peptide–targeted therapies.

1

CGRP-targeted therapies reduced monthly migraine headache days by about 2 days compared to placebo in chronic migraine patients.
2

The systematic review included 43 trials with 14,725 adult patients, establishing high-certainty evidence for several CGRP therapies.
3

Fremanezumab and erenumab showed high-certainty evidence for achieving at least a 50% reduction in migraine days.
4

Galcanezumab likely reduced dropout rates due to any cause, while erenumab and atogepant increased risks of constipation and nausea.
5

The review highlighted the need for larger independent trials to assess long-term safety and effectiveness of CGRP therapies.

1